{"entity":{"id":"paper-marquart-genome-driven-oncology-benefit-jama-oncol-2018","kind":"paper","name":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","aka":[],"tldr":"Counting every drug approved for a gene change up to January 2018, about 8 in 100 Americans with advanced cancer were eligible for one and about 5 in 100 were estimated to benefit.","summary":"A retrospective cross-sectional estimate built from public data: the number of people in the United States with advanced or metastatic cancer, the drugs the FDA approved from January 2006 to January 2018, response rates and durations from their labels, and published frequencies of the genomic alterations each drug required. Thirty-one drugs with 38 indications met the definition of genome-targeted or genome-informed therapy.\n\nThe share of patients eligible for genome-targeted therapy rose from 5.09 per cent (28,729 of 564,830) in 2006 to 8.33 per cent (50,811 of 609,640) in 2018. The share estimated to benefit rose from 0.70 per cent to 4.90 per cent. For the broader genome-informed category, eligibility reached 15.44 per cent and estimated benefit 6.62 per cent in 2018. The median response rate for genome-informed drugs was 54 per cent and the median duration of response 29.5 months. The authors concluded that these drugs had helped a minority of patients with advanced cancer.","asOf":"2026-10-20","links":[{"label":"Marquart, Chen and Prasad, JAMA Oncol 2018","url":"https://doi.org/10.1001/jamaoncol.2018.1660"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29710180/"}],"tags":["precision"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-drivers-vs-actionable"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"journal":"JAMA Oncology","year":2018,"doi":"10.1001/jamaoncol.2018.1660","pmid":"29710180","authors":"Marquart J, Chen EY, Prasad V","paperType":"observational","findings":["Eligibility for genome-targeted therapy: 5.09 per cent of US patients with metastatic cancer in 2006, 8.33 per cent in 2018.","Estimated benefit from genome-targeted therapy: 0.70 per cent in 2006, 4.90 per cent in 2018.","Genome-informed therapy in 2018: 15.44 per cent eligible, 6.62 per cent estimated to benefit; median response rate 54 per cent, median duration of response 29.5 months."],"whatItMeans":"Precision drugs can work very well for the people they fit, and by 2018 they fitted a small share of people with advanced cancer. The figure has risen since with every new approval; it is a baseline, not a current count.","caveats":["Benefit is estimated from response rates on labels, not measured in patients, and response is not the same as longer life.","The estimate stops at January 2018 and approvals since then, including tumour-agnostic ones, are not counted.","United States only; access elsewhere differs."]},"route":"/key-papers/paper-marquart-genome-driven-oncology-benefit-jama-oncol-2018/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"term":[{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","route":"/terms/cancer-drivers-vs-actionable/"}],"journal":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/"}]}}